• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Matthew Galsky interprets latest atezolizumab/chemo results in bladder cancer

Video

Matthew D. Galsky, MD, interprets the results from the final overall survival (OS) analysis of the IMvigor130 trial, which were shared during the 2021 American Association for Cancer Research Virtual Annual Meeting. The IMvigor130 trial randomized patients with metastatic urothelial carcinoma to atezolizumab plus platinum/gemcitabine; atezolizumab alone; or placebo plus platinum/gemcitabine.

Galsky says that the final OS analysis comparing atezolizumab/chemo versus placebo/chemo did not show a statistically significant OS benefit with atezolizumab, and thus, OS follow-up remains ongoing. Galsky also discusses the finding from an exploratory analysis which suggest that outcomes with atezolizumab/chemo might be affected by the specific platinum regimen used.

Galsky is professor of Medicine; director of Genitourinary Medical Oncology; director of the Novel Therapeutics Unit; and co-director of the Center of Excellence for Bladder Cancer at the Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai.

Related Videos
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Ryan L. Steinberg, MD, answers a question during a Zoom video interview
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.